Profound Medical (TSE:PRN) Raised to Strong-Buy at Raymond James Financial

Profound Medical (TSE:PRN) was upgraded by equities research analysts at Raymond James Financial from a “moderate buy” rating to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Profound Medical Trading Up 1.6%

PRN stock opened at C$10.44 on Monday. The business has a fifty day moving average price of C$9.63 and a 200 day moving average price of C$9.45. The company has a debt-to-equity ratio of 12.56, a current ratio of 6.56 and a quick ratio of 14.98. The stock has a market capitalization of C$379.37 million, a price-to-earnings ratio of -8.42 and a beta of 1.26. Profound Medical has a fifty-two week low of C$5.23 and a fifty-two week high of C$12.40.

Profound Medical (TSE:PRN) last released its quarterly earnings results on Thursday, May 7th. The company reported C$0.26 earnings per share (EPS) for the quarter. The business had revenue of C$7.42 million during the quarter. Profound Medical had a negative return on equity of 78.75% and a negative net margin of 206.94%. Analysts expect that Profound Medical will post -1.9000001 EPS for the current fiscal year.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.